304 related articles for article (PubMed ID: 17952653)
21. Cannabinoids: novel medicines for the treatment of Huntington's disease.
Sagredo O; Pazos MR; Valdeolivas S; Fernandez-Ruiz J
Recent Pat CNS Drug Discov; 2012 Apr; 7(1):41-8. PubMed ID: 22280340
[TBL] [Abstract][Full Text] [Related]
22. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
23. Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease.
Baul HS; Manikandan C; Sen D
Brain Res Bull; 2019 Mar; 146():244-252. PubMed ID: 30664919
[TBL] [Abstract][Full Text] [Related]
24. Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies.
Fernández-Ruiz J; Gómez-Ruiz M; García C; Hernández M; Ramos JA
Methods Enzymol; 2017; 593():175-198. PubMed ID: 28750802
[TBL] [Abstract][Full Text] [Related]
25. Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.
Fernández-Ruiz J; Moro MA; Martínez-Orgado J
Neurotherapeutics; 2015 Oct; 12(4):793-806. PubMed ID: 26260390
[TBL] [Abstract][Full Text] [Related]
26. Endocannabinoids and basal ganglia functionality.
Fernández-Ruiz J; Lastres-Becker I; Cabranes A; González S; Ramos JA
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):257-67. PubMed ID: 12052041
[TBL] [Abstract][Full Text] [Related]
27. Differential cannabinoid receptor expression during reactive gliosis: a possible implication for a nonpsychotropic neuroprotection.
De Filippis D; Steardo A; D'Amico A; Scuderi C; Cipriano M; Esposito G; Iuvone T
ScientificWorldJournal; 2009 Mar; 9():229-35. PubMed ID: 19347234
[TBL] [Abstract][Full Text] [Related]
28. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
[TBL] [Abstract][Full Text] [Related]
29. The therapeutic potential of cannabinoids for movement disorders.
Kluger B; Triolo P; Jones W; Jankovic J
Mov Disord; 2015 Mar; 30(3):313-27. PubMed ID: 25649017
[TBL] [Abstract][Full Text] [Related]
30. The role of cannabinoids and leptin in neurological diseases.
Agar E
Acta Neurol Scand; 2015 Dec; 132(6):371-80. PubMed ID: 25880465
[TBL] [Abstract][Full Text] [Related]
31. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
Han QW; Yuan YH; Chen NH
Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease.
Little JP; Villanueva EB; Klegeris A
Mini Rev Med Chem; 2011 Jun; 11(7):582-90. PubMed ID: 21699489
[TBL] [Abstract][Full Text] [Related]
33. Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.
Junior NCF; Dos-Santos-Pereira M; Guimarães FS; Del Bel E
Neurotox Res; 2020 Jan; 37(1):12-29. PubMed ID: 31637586
[TBL] [Abstract][Full Text] [Related]
34. Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease.
Burgaz S; García C; Gómez-Cañas M; Muñoz E; Fernández-Ruiz J
Molecules; 2019 Jul; 24(15):. PubMed ID: 31349553
[TBL] [Abstract][Full Text] [Related]
35. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures.
Kreutz S; Koch M; Ghadban C; Korf HW; Dehghani F
Exp Neurol; 2007 Jan; 203(1):246-57. PubMed ID: 17010339
[TBL] [Abstract][Full Text] [Related]
36. Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.
Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
Pharmacol Res; 2016 Aug; 110():205-215. PubMed ID: 27013280
[TBL] [Abstract][Full Text] [Related]
37. The seek of neuroprotection: introducing cannabinoids.
Martínez-Orgado J; Fernández-López D; Lizasoain I; Romero J
Recent Pat CNS Drug Discov; 2007 Jun; 2(2):131-9. PubMed ID: 18221224
[TBL] [Abstract][Full Text] [Related]
38. Neuroprotection with the cannabigerol quinone derivative VCE-003.2 and its analogs CBGA-Q and CBGA-Q-Salt in Parkinson's disease using 6-hydroxydopamine-lesioned mice.
Burgaz S; García C; Gómez-Cañas M; Navarrete C; García-Martín A; Rolland A; Del Río C; Casarejos MJ; Muñoz E; Gonzalo-Consuegra C; Muñoz E; Fernández-Ruiz J
Mol Cell Neurosci; 2021 Jan; 110():103583. PubMed ID: 33338634
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid receptors and their role in neuroprotection.
van der Stelt M; Di Marzo V
Neuromolecular Med; 2005; 7(1-2):37-50. PubMed ID: 16052037
[TBL] [Abstract][Full Text] [Related]
40. Cannabinoids as neuroprotective agents in traumatic brain injury.
Biegon A
Curr Pharm Des; 2004; 10(18):2177-83. PubMed ID: 15281893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
